EP0076066A1 - Penicillin-Derivate - Google Patents
Penicillin-Derivate Download PDFInfo
- Publication number
- EP0076066A1 EP0076066A1 EP82304892A EP82304892A EP0076066A1 EP 0076066 A1 EP0076066 A1 EP 0076066A1 EP 82304892 A EP82304892 A EP 82304892A EP 82304892 A EP82304892 A EP 82304892A EP 0076066 A1 EP0076066 A1 EP 0076066A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- hours
- general formula
- acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C(C(C)(C)SC1*C(c2ccccc2)N=Cc(cccc2OC)c2N=O)N1C(C)=* Chemical compound C*C(C(C)(C)SC1*C(c2ccccc2)N=Cc(cccc2OC)c2N=O)N1C(C)=* 0.000 description 3
- BTETXONUHJGWGO-UHFFFAOYSA-N CC(C1O)=CC=C(CO)C1C=C Chemical compound CC(C1O)=CC=C(CO)C1C=C BTETXONUHJGWGO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
Definitions
- the present invention relates to penicillin derivatives, their preparation and pharmaceutical compositions containing them.
- Penicillins are well known as excellent antibiotics due to their selective toxicity to bacteria.
- the penicillin antibiotic has a serious defect, that is it may disturb the beneficial bacterial colonies ordinarily present in living bodies, particularly the intestinal bacterial colonies, since it may be also antibacterially active against the beneficial bacteria. This defect is very serious when such an antibiotic is orally administered.
- "microbisme selectionne et substitue” is caused resulting in colitis and diarrhoea.
- the present invention is concerned with antibiotics without this defect. More particularly, the present invention relates to compounds obtained by chemically modifying a penicillin, antibacterial activity being lost by such chemical modification but recovered when the compound is absorbed into a living body.
- the compounds of the invention can be formulated into pharmaceutical compositions to provide a medicine exhibiting antibacterial activity similar to a penicillin antibiotic in a living body.
- Compounds of the present invention (hereinafter referred to as the present compound) have the general formula (I): wherein R 1 is or and wherein R 4 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a physiologically acceptable cation, preferably an alkali metal cation.
- the present compound may therefore be in the form of a salt other than an alkali metal salt, for example an alkali earth metal salt, an aluminium salt or an amnonium salt.
- the present compound, and indeed all penicillin derivatives described and illustrated by formulae herein, have the usual absolute stereochemistry of penicillins of 3S:5R:6R.
- the present compound is derived from a penicillin antibiotic by a chemical modification. It is absorbed into a living body without affecting the bacterial colonies ordinarily present in living bodies and shows an antibacterial activity only when entering into blood, therefore, the present compound is an antibiotic of the new type quite different from the conventional penicillin antibiotics.
- the present compound may be synthesized by the following processes.
- the present compound has low toxicity and exhibits an antibacterial activity in a living body without affecting the intestinal Jacterial colonies.
- the present compound can be useful in the same field as the conventional penicillin antibiotics since the present compound is transformed into a penicillin antibiotic in a living body.
- the present compound can be used in a dosage unit form such as a drug or a pharmaceutical composition.
- the composition may contain 0.01 to 99.5% by weight, generally 0.1 to 90% by weight of the present compound as an active ingredient.
- the pharmaceutical composition contains a pharmaceutically acceptable carrier, diluent or adjuvant as well as at least one of the present compound.
- the composition may contain filler, extender, binder, wetting agent, disintegrant, retarder of dissolution, accelerator of reabsorption, adhesive carrier and/or lubricant, for example, starch, mannitol, silicic acid, cellulose derivative, gelatin, alginate, glycerol, agar, calcium carbonate, sodium hydrogen carbonate, paraffin, quartarnary ammonium compound, glycerol monostearate, kaolin, bentonite, talc, aluminum stearate, magnesium stearate, polyethylene glycol and the like.
- the pharmaceutical composition may be administered orally or rectally or by injection.
- the dosage form for oral administration may be tablet, capsule, powder, granule, pill, ampoule or the like.
- the composition may be in the form of pharmaceutically acceptable emulsion, solution, suspension and the like.
- a syrup or elixir may contain an inert diluent such as water and paraffin and may be used as a liquid composition suitable for oral administration. These composition may contain an adjuvant such as wetting agent, edulcorant and seasoning agent.
- a suppository containing the present compound as an active ingredient may contain polyethylene glycol and/or fatty acid or ester thereof.
- the pharmaceutical composition for injection may be a stearilized aqueous or nonaqueous solution, suspension or emulsion and may contain, for example, propylene glycol, polyethylene glycol, olive oil and the like.
- the present compound may be useful for the same as the conventional penicillin antibiotics and effective in treating an infectious disease due to bacteria such as Streptococcus, Pneumococcus, Gonococcus, diphteria bacillus, Staphylococcus, Spirochaeta, Actinomyces, Shigella, E. coli, Myxomycetes, Enterecoccus, Meningococcus and the like.
- bacteria such as Streptococcus, Pneumococcus, Gonococcus, diphteria bacillus, Staphylococcus, Spirochaeta, Actinomyces, Shigella, E. coli, Myxomycetes, Enterecoccus, Meningococcus and the like.
- the diseases to be able to be treated with the present compound is exemplified as follows; tonsilitis, pharyngitis, laryngitis, wound, burn, postoperative secondary infection, lymphadenitis, septicemia, bacterial endocarditis, pneumonia, pulmonary suppuration, bronchitis, scarlet fever, gonorrhea, cystitis, pyothorax, urethritis, bacterial dysentery, meningitis, diphtheria, otitis media, carbuncle, actinomycosis and the like.
- the dose of the drug or the pharmaceutical composition of the present compound may depend on the degree of the infection and the condition of the patient, and generally the dose of 0.1 to 10 g may be administered to an adult patient per one day, divided into several times.
- the filtrate was subjected to distillation to evaporate off the solvent thereof, and the residue was mixed with 100 ml of water and the pH of the mixture was adjusted to 2 by the addition of aqueous 5% solution of hydrochloric acid.
- the thus separated solid material was extracted with 200 ml of ethyl acetate, washed three times with water and dried on anhydrous magnesium sulfate. Then the solvent was distilled off from the dried extract.
- Example 9 In the same manner as that in Example 9 except for using 378 mg of chloromethyl ethyl ether instead of 500 mg of chloromethyl methyl ether in Example 9, 680 mg of a crude product was obtained. Recrystallizing from a mixed solvent of ethyl acetate and n-hexane, 571 mg of the purified product was obtained with a yield of 70%.
- Acute toxicity of the present compounds were determined as follows.
- Each of the present compounds was dispersed in a physiological saline solution.
- the dispersion was administered to an ICR-JCL mouse orally by a stomach sonde or intraperitoneally by injection at a predetermined amount.
- LD 50 value was obtained from the cumulative mortality of the treated mice by applying the data to the Litchfield-Wilcoxon's graphical method. All of the present compounds gave LD SO value of more than 10 g/kg in both oral and intraperitoneal administrations.
- the LD 50 value of the conventional penicillin as a comparative antibiotic is about 5 g/kg.
- mice one group consisting of five female ICR mice of 6-week-old
- mice one group consisting of five female ICR mice of 6-week-old
- feces of each mouse was collected and diluted with an anaerobic diluent (phosphoric buffer solution) of 100 times volume and ground. 0.1 ml of the diluted and ground feces was smeared on each culture medium shown in Table 1 and cultured aerobically or anaerobically (according to the anaerobic glove box method) under each condition shown in Table 1. The number of each bacterium shown in Table 1 was counted.
- anaerobic diluent phosphoric buffer solution
- Antibacterial activity of the present compounds was examined as follows.
- Each bacterial strain was inoculated into the Mueller-Hinton's culture medium and cultured at 37°C for 18 to 48 hours.
- the culture medium was diluted so as to contain 1 x 10 6 cells of the bacteria per one ml, and the obtained medium was used as the bacterial specimen.
- Agar plates were prepared by adding one part by weight of each solution of the present compounds having a predetermined concentration to nine parts by weight of Mueller-Hinton's culture medium.
- a loopful amount of the bacterial specimen prepared above was smeared to make a streak of about 2 cm on each agar plate and cultured at 37°C for 18 to 24 hours.
- the minimum concentration for completely inhibiting proliferation of the bacteria (referred as MIC) was determined.
- a rat liver homogenate (S-9, manufactured by Oriental Yeast Company, Japan) was used in the following composition per one ml (hereinafter referred to as S-9 mix).
- S-9 mix a rat liver homogenate
- 0.1 ml of each solution of the present compounds at a concentration of 100 ug/ml was mixed with 0.9 ml of S-9 mix or 0.9 ml of 0.1 M phosphoric buffer solution (as a control) and the obtained mixture was incubated at 37°C for 20 min with shaking.
- Staphylococcus aureus IAM 1011 was inoculated into a Mueller-Hinton's culture medium and cultured at 37°C for 18 hours.
- the culture medium was adjusted to a cell concentration of 1 x 10 8 per one ml and mixed with 50 times by volume of Mueller-Hinton's agar culture medium to obtain an agar plate.
- a penicillin cup of 8 mm in diameter was placed on the agar plate prepared above, and into the cup 0.1 ml of the mixture was introduced and allowed to stand at 4°C for 2 hours and then cultured at 37°C for 18 hours to measure the diameter of a circle in which the proliferation of bacteria was inhibited (proliferation-inhibiting circle).
- the results are shown in Table 4.
- the proliferation-inhibiting index is shown with the ratio (%) of the diameter of the proliferation-inhibiting circle obtained by using each of the present compounds to that obtained by using the comparative compound(conventional penicillin antibiotic).
- the antibacterial activity of the present compound is activated by an enzyme in a living body, although it itself shows a low antibacterial activity in the absence of an activating enzyme.
- Escherichia coli IFO 12734 (1.4 x 10 8 ) was inoculated intraperitoneally to ddY-SPF mice (a group consisting of 20 mice). Just after and at 4 hours after the infection, each of the present compounds was administered orally at a dose of 500 mg/kg and the mortality of the mice due to the infection was observed for 7 days. More than 35% of the mice administered with the present compound survived even on the 7th day after the infection, while all mice without the administration with the present compound died on the 2nd day after infection.
- the present compound and lactose was mixed and then an aqueous solution of hydroxypropylcellulose was admixed, and the mixture was kneaded, dried and pulverized. Then magnesium stearate dispersed previously into starch was admixed and the mixture was made into a tablet by the conventional method for tabletting.
- the present compound, starch and lactose were mixed, and an aqueous solution of hydroxypropylcellulose was admixed and the mixture was dried and pulverized.
- the pulverized material was sifted by 12 to 48 mesh sieves to obtain a granule.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56149870A JPS5852292A (ja) | 1981-09-22 | 1981-09-22 | 抗生物質と医薬剤 |
JP56149869A JPS5852291A (ja) | 1981-09-22 | 1981-09-22 | ペニシリン系抗生物質誘導体とその医薬剤 |
JP149869/81 | 1981-09-22 | ||
JP149870/81 | 1981-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0076066A1 true EP0076066A1 (de) | 1983-04-06 |
EP0076066B1 EP0076066B1 (de) | 1986-11-26 |
Family
ID=26479636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP82304892A Expired EP0076066B1 (de) | 1981-09-22 | 1982-09-16 | Penicillin-Derivate |
Country Status (4)
Country | Link |
---|---|
US (1) | US4540689A (de) |
EP (1) | EP0076066B1 (de) |
AU (1) | AU559689B2 (de) |
DE (1) | DE3274453D1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632961B1 (en) * | 1998-05-22 | 2003-10-14 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
EP1138333B1 (de) * | 1999-10-12 | 2004-02-25 | Daiichi Suntory Pharma Co., Ltd. | Arzneimittel zur oralen verabreichung |
PA8579701A1 (es) * | 2002-08-23 | 2005-05-24 | Pfizer Prod Inc | Profarmaco inhibidor de beta-lactamasa |
BRPI0410936A (pt) * | 2003-06-05 | 2006-06-27 | Pfizer Prod Inc | pró-fármaco inibidor da beta-lactamase |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB630264A (en) * | 1945-12-20 | 1949-10-10 | Merck & Co Inc | Process for preparing esters of penicillin g |
GB1081093A (en) * | 1964-03-17 | 1967-08-31 | Rech S Et D Applic Scient Et M | Improvements in or relating to 6-[d(-)-alpha-(amino-phenylacetamido)]-penicillanic acid derivatives |
DE1940571A1 (de) * | 1968-08-08 | 1970-02-19 | Pliva Pharm & Chem Works | Neue Penicilline und Verfahren zu deren Herstellung |
FR2085746A1 (de) * | 1970-03-26 | 1971-12-31 | Gallardo Antonio Sa | |
USB547208I5 (de) * | 1972-12-08 | 1976-02-24 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US547208A (en) * | 1895-10-01 | Net tucker hall | ||
FR2086746A5 (de) * | 1970-04-07 | 1971-12-31 | Alsthom | |
US4342768A (en) * | 1979-10-22 | 1982-08-03 | Pfizer Inc. | Bis-esters of 1,1-alkanediols with 6-beta-hydroxymethylpenicillanic acid 1,1-dioxide and beta-lactam antibiotics |
US4317775A (en) * | 1980-01-07 | 1982-03-02 | Hoffmann-La Roche Inc. | Amoxicillin derivatives |
IT1134541B (it) * | 1980-12-02 | 1986-08-13 | Juan Scalesciani | Derivato della ammino-penicillina,processo per la sua preparazione e composizioni terapeutiche che lo comprendono come principio attivo |
-
1982
- 1982-09-16 US US06/418,760 patent/US4540689A/en not_active Expired - Fee Related
- 1982-09-16 EP EP82304892A patent/EP0076066B1/de not_active Expired
- 1982-09-16 DE DE8282304892T patent/DE3274453D1/de not_active Expired
- 1982-09-16 AU AU88472/82A patent/AU559689B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB630264A (en) * | 1945-12-20 | 1949-10-10 | Merck & Co Inc | Process for preparing esters of penicillin g |
GB1081093A (en) * | 1964-03-17 | 1967-08-31 | Rech S Et D Applic Scient Et M | Improvements in or relating to 6-[d(-)-alpha-(amino-phenylacetamido)]-penicillanic acid derivatives |
DE1940571A1 (de) * | 1968-08-08 | 1970-02-19 | Pliva Pharm & Chem Works | Neue Penicilline und Verfahren zu deren Herstellung |
FR2085746A1 (de) * | 1970-03-26 | 1971-12-31 | Gallardo Antonio Sa | |
USB547208I5 (de) * | 1972-12-08 | 1976-02-24 |
Non-Patent Citations (2)
Title |
---|
BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, no. 1, 1968, pages 420-4; * |
JOURNAL OF THE CHEMICAL SOCIETY, 1965, part II, pages 1565-3016; * |
Also Published As
Publication number | Publication date |
---|---|
US4540689A (en) | 1985-09-10 |
DE3274453D1 (en) | 1987-01-15 |
AU559689B2 (en) | 1987-03-19 |
EP0076066B1 (de) | 1986-11-26 |
AU8847282A (en) | 1983-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH617202A5 (de) | ||
US4053360A (en) | Enzymatic preparation of 6-D-(-)-α-amino-α-(p-hydroxyphenylacetamino)penicillin acid | |
AU2006300882B2 (en) | Crystalline sodium salt of cephalosporin antibiotic | |
EP0076066A1 (de) | Penicillin-Derivate | |
EP0075449B1 (de) | Penicillin-Derivate | |
US4496561A (en) | Cephalosporin derivative | |
EP0113242B1 (de) | Cephalosporinderivate | |
EP0075450B1 (de) | Cephalosporinderivate | |
EP0075451B1 (de) | Cephalosporinderivate | |
AU600536B2 (en) | Crystalline salts of {3s(z)}-2-{{{1-(2-amino-4-thiazolyl) -2-{{2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl}-amino-2- oxoethylidene}-amino}oxy}acetic acid | |
EP0075452B1 (de) | Cephalosporinderivate | |
US4285939A (en) | Cephalosporin derivatives, and antibacterial drugs containing the derivatives | |
EP0113243B1 (de) | Cephalosporinverbindungen | |
US4446137A (en) | Cephalosporin derivative and pharmaceutical composition containing the derivative | |
EP0113245B1 (de) | Cephalosporinverbindungen | |
US4734409A (en) | Cephalosporin derivative, process for producing the same and pharmaceutical composition containing the same | |
JP4730879B2 (ja) | キガマイシノン類及びその製造方法、並びに、該キガマイシノン類を含む薬用組成物 | |
Kobori et al. | Synthesis and biological properties of 3-[(Z)-2-(1, 2, 3-thiadiazolyl) ethenyl]-substituted cephalosporins and related compounds: new oral cephalosporins | |
JPH0160010B2 (de) | ||
FR2538393A1 (fr) | Procede de preparation d'oxacephalosporines, nouveaux produits ainsi obtenus et compositions pharmaceutiques antibacteriennes les renfermant | |
CH640239A5 (en) | Process for the preparation of novel cephem-4-carboxylic acid compounds | |
JPH0234357B2 (ja) | Sefuarosuhorinjudotaioyobigaijudotaioganjusuruyakuzai | |
JPH0240071B2 (ja) | Sefuarosuhorinjudotaioyobigaijudotaioganjusuruyakuzai | |
JPH021836B2 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LI SE |
|
17P | Request for examination filed |
Effective date: 19830924 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB IT LI SE |
|
REF | Corresponds to: |
Ref document number: 3274453 Country of ref document: DE Date of ref document: 19870115 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
RIN2 | Information on inventor provided after grant (corrected) |
Free format text: MUTO, SHIGEAKI * NIIMURA, KOUICHI * ANDO, TAKAO * KANNO, AKIHIKO * FURUSHO, TAKAO * YOSHIKUMI, CHIKAO |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19890908 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19890929 Year of fee payment: 8 |
|
ITTA | It: last paid annual fee | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19900803 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19900917 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19900919 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19900925 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19900930 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19901031 Year of fee payment: 9 |
|
BERE | Be: lapsed |
Owner name: KUREHA KAGAKU KOGYO K.K. Effective date: 19900930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19910916 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19910930 Ref country code: CH Effective date: 19910930 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19920529 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19920602 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 82304892.1 Effective date: 19910527 |